



Case Report



Spontaneous coronary artery dissection and proximal LAD stenosis in a young male with HIV: A case report

Stella-Maria Kyvelou[®], Konstantinos Kalogeras[®], Nikolaos Vythoulkas-Biotis[®], Panteleimon Pantelidis[®], Georgios Angelos Papamikroulis[®], Manolis Vavuranakis

3rd Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Thoracic Diseases Hospital of Athens "Sotiria", Athens, Greece

Article info

Article History:
Received: July 25, 2024
Revised: May 20, 2025
Accepted: July 23, 2025
epublished: December 17, 2025

*Corresponding Author: Nikolaos Vythoulkas-Biotis, Email: vbnikos@gmail.com

Abstract

HIV/AIDS patients under antiretroviral therapy have increased cardiovascular risk. Spontaneous coronary artery dissection, an uncommon yet recognized cause of acute coronary syndrome, typically affects middle-aged females, especially during pregnancy. We present a rare case of SCAD and proximal left anterior descending stenosis in a 45-year-old male with HIV.

Keywords: Human immunodeficiency virus, Acquired immune deficiency syndrome, Antiretroviral therapy, Myocardial infarction, Spontaneous coronary artery dissection

Introduction

Spontaneous Coronary Artery Dissection (SCAD) is a distinct and uncommon cause of non-atherosclerotic myocardial infarction (MI) occurring in the middle-aged population, with a higher incidence observed among women during the peripartum period. SCAD is estimated to account for less than 1% of all acute myocardial infarctions in both sexes.1 It occurs when a hematoma forms within the middle layer of the coronary artery wall, creating a false lumen.^{1,2} The precise underlying causes remain unknown, however, it has been linked to emotional and physical stress, pharmaceutical substances, hormonal stimuli, as well as various inflammatory conditions.1 Human immunodeficiency virus (HIV) and antiretroviral therapy have immediate effects on coronary arteries through a variety of mechanisms, such as endothelial dysfunction, vascular injury, and progression of atherosclerosis.3 We report the case of a 45-yearold male with a diagnosis of HIV, under antiretroviral therapy who presented with an incident of SCAD along with a stenosis of the proximal left anterior descending artery (LAD).

Case Presentation

A 45-year-old male was admitted to our hospital with ongoing chest pain. Upon admission, his blood pressure was 120/70mmHg, and his heart rate was 100bpm. His electrocardiogram revealed no significant changes and his peak troponin levels were 513.4 pg/mL. Point-of-

care ultrasound (POCUS) was performed and showed a normal dimension left ventricle with normal systolic function (EF = 60%) and right ventricular systolic pressure (RVSP): 25-30mmHg.

As for cardiovascular risk factors, our patient was an active smoker and positive for HIV infection, under highly active antiretroviral therapy (HAART) with Dolutegravir/Abacavir/Lamivudine. Upon his arrival at our center, he reported that he had an undetectable viral load. He had no other risk factors of note.

He underwent a coronary angiography which revealed a moderate stenosis in proximal LAD as well as an elongated intracoronary clarification extending from the proximal to the middle segment of the vessel with normal distal flow, TIMI III (Figure 1A-B), (Supplementary Files, Video 1 - 2). We performed an intravascular ultrasound (IVUS) which confirmed the coronary artery dissection with a length of 3.9mm² (Figure 2).

After the first angiography, no intervention was performed, and he was treated with dual antiplatelet therapy (DAPT) (Aspirin and Clopidogrel). Five days later we performed another coronary angiography, which revealed signs of healing of the dissected vessel area (Figure 1C), (Supplementary Files, Video 3). Simultaneously, an instantaneous wave-free ratio (IFR) was performed, to assess the severity of the proximal LAD lesion, which was not significant in three consecutive measurements (IFR = 0.96, 0.95, 0.96). The patient was discharged with instructions to continue DAPT and






Figure 1. A) Initial Coronary angiography showing the dissected area of the vessel, B) the proximal LAD stenosis, C) Follow-up angiography 5-days later showing signs of healing




Figure 2. Intravascular ultrasound showing the area of the dissection

reevaluation of the dissection with a future angiography. At the same time, his HIV treatment changed to Doravirine/ Tenofovir/Lamivudine, due to increased cardiovascular risk caused by the current antiretroviral therapy.

5 months later a new coronary angiography and an optical coherence tomography (OCT) were performed to evaluate the healing of the dissection site (Supplementary Files, Video 4). Coronary angiography revealed a decreased intracoronary clearance at the site of the dissection and improved angiographic image in the presence of mild calcification (Supplementary Files, Video 5). OCT revealed severe proximal LAD stenosis (MLA: 2.1mm²) (Figure 3)

The patient (symptom-free) was once again discharged with instructions for DAPT continuation and future consideration of percutaneous coronary intervention (PCI) to LAD versus minimally invasive coronary artert bypass grafting (CABG) with LIMA to LAD.

Discussion

HIV represents a well-established cause for the development of cardiovascular disease (CVD). The underlying pathophysiological mechanism of both HIV infection and antiretroviral therapy is associated with the




Figure 3. OCT of the dissected area and the proximal stenosis at the follow-up angiography

progression of atherosclerosis, subsequently establishing coronary artery disease.^{4,5} In individuals with HIV, the presence of chronic inflammation and endothelial dysfunction may contribute to an increased susceptibility to vascular damage, potentially including SCAD.^{4,5}

The diagnosis of SCAD can be challenging, because of its resemblance with other causes of ACS, such as atherosclerotic plaque rupture. Coronary angiography alone is not always enough to ensure the diagnosis, because SCAD can be presented with a variety of angiographic results.⁶ In the majority of the cases intravascular techniques, such as OCT usually confirm the diagnosis with the presence of intramural hematoma and a false lumen.⁶ In the present case, IVUS was used to establish the diagnosis.

Guideline-directed medical therapy for SCAD is initially conservative, involving a wall self-healing process with dual antiplatelet therapy, and beta blockers leading to complete angiographic resolution of the lesion in most cases. However, optimal medical therapy is limited to expert opinions, due to the absence of clinical trials supporting evidence-based management. This approach is preferred as revascularization comes with a number of complications. This includes entering the false lumen with the guiding wire, the extension of intramural hematoma, or long-term complications with stent malposition and thrombosis. However, there are high-risk

situations where revascularization is appropriate, this includes the dissection of the left main coronary artery, a thrombolysis in myocardial infarction (TIMI) grade 0-1 proximally, hemodynamic compromise, and persistent arrhythmia. In these cases, imaging-guided PCI strategies involving long stent coverage of the dissection, avoiding pre-dilatation, or multi-stenting approaches beginning from the edges and finishing at the middle part of the dissection are recommended. The decision between medical therapy revascularization (PCI or CABG) should be individualized based on the extent of coronary involvement and the patient's clinical presentation.

Abacavir is a nucleoside analog reverse-transcriptase inhibitor that is commonly used in HIV patients, alongside newer drug classes like integrase strand transfer inhibitors and reverse transcriptase inhibitors, for improved efficacy and reduced side effects. Despite its therapeutic value, Abacavir has been implicated in increasing cardiovascular risk.9 There is an ongoing debate in the literature, as some of the studies strengthen the hypothesis that there is a connection between abacavir and the development of ACS, while others show no significant risk.9 The flagship study was published by the D:A:D study group in 2008, which showed an increased risk of myocardial infarction in patients treated with abacavir.10 The reason for the debate is that this study in addition to several followup studies, that also supported the initial hypothesis, included a sample of patients with predisposing risk factors to cardiovascular disease, such as hypertension, dyslipidemia, and smoking.9 It is worth noting that active smoking likely contributed to the vascular susceptibility and serves as a confounder in the present case. The underlying mechanisms by which abacavir is connected to acute coronary syndrome are still not completely understood. Some possible explanations are: 1) platelet activation that is related to arterial thrombosis¹¹, 2) interaction between human leukocytes and endothelial cells which may contribute to vascular damage and progression of atherosclerosis.12

In our case, a significant change in his HIV treatment was made and abacavir was replaced by tenofovir. It has been previously demonstrated that patients switching to a tenofovir based regimen have an improved lipid profile, with a substantial decrease in total cholesterol and LDL levels, thus a reduced cardiovascular risk.¹³ No direct correlation between antiretroviral therapy and SCAD has yet been proven.

Conclusion

This case report shows the importance of considering SCAD as a potential cause of ACS in individuals with HIV. It also highlights the need for a comprehensive and multidisciplinary approach to diagnosis and management, considering the unique challenges posed by antiretroviral therapy and the increased cardiovascular risk associated with HIV infection. Further research is warranted to

explore the underlying mechanisms of SCAD in this population and to develop reliable treatment strategies.

Acknowledgements

The authors have no acknowledgements to declare.

Authors' Contribution

Conceptualization: Stella-Maria Kyvelou, Nikolaos Vythoulkas-Biotis.

Data curation: Stella-Maria Kyvelou.

Formal analysis: Panteleimon Pantelidis, Georgios Angelos Papamikroulis.

Project administration: Stella-Maria Kyvelou, Manolis Vavuranakis.

Investigation: Stella-Maria Kyvelou, Konstantinos Kalogeras.

Methodology: Nikolaos Vythoulkas-Biotis, Konstantinos Kalogeras.

Resources: Manolis Vavuranakis.

Supervision: Stella-Maria Kyvelou, Manolis Vavuranakis.

Validation: Stella-Maria Kyvelou, Konstantinos Kalogeras.

Visualization: Panteleimon Pantelidis, Georgios Angelos Papamikroulis.

Writing—original draft: Stella-Maria Kyvelou, Nikolaos Vythoulkas-Biotis.

Writing—review & editing: Stella-Maria Kyvelou, Nikolaos Vythoulkas-Biotis, Konstantinos Kalogeras.

Competing Interests

The authors declare that they have no competing interests.

Ethical Approval

An informed consent was obtained from the patient.

Funding

This study received no funding.

Supplementary Files

Video 1: Initial coronary angiography showing the intracoronary clearance at the site of the dissection

Video 2: Proximal LAD stenosis in the first angiography

Video 3: Follow-up angiography 5 days later showing signs of healing at the dissected area

Video 4: Full OCT run evaluating the healing of the dissection Video 5: Improved angiographic result in the follow-up angiography 5 months later

References

- Kim ES. Spontaneous coronary-artery dissection. N Engl J Med. 2020;383(24):2358-70. doi: 10.1056/NEJMra2001524
- Adlam D, Tweet MS, Gulati R, Kotecha D, Rao P, Moss AJ, et al. Spontaneous coronary artery dissection: pitfalls of angiographic diagnosis and an approach to ambiguous cases. JACC Cardiovasc Interv. 2021;14(16):1743-56. doi: 10.1016/j. jcin.2021.06.027
- Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation. 2008;118(2):e36-40. doi: 10.1161/circulationaha.107.189625
- Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(Suppl 3):S375-82. doi: 10.1093/infdis/jis200
- Kaplan-Lewis E, Aberg JA, Lee M. Atherosclerotic cardiovascular disease and anti-retroviral therapy. Curr HIV/ AIDS Rep. 2016;13(5):297-308. doi: 10.1007/s11904-016-0331-y
- Saw J, Aymong E, Sedlak T, Buller CE, Starovoytov A, Ricci D, et al. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors

- and cardiovascular outcomes. Circ Cardiovasc Interv. 2014;7(5):645-55. doi: 10.1161/circinterventions.114.001760
- Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation. 2018;137(19):e523-57. doi: 10.1161/cir.0000000000000564
- 8. Pristera N, Chaudhury P, Van Iterson EH, Cho LS. Spontaneous coronary artery dissection: principles of management. Cleve Clin J Med. 2021;88(11):623-30. doi: 10.3949/ ccjm.88a.20162
- Alvarez A, Orden S, Andújar I, Collado-Diaz V, Núñez-Delgado S, Galindo MJ, et al. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. AIDS. 2017;31(13):1781-95. doi: 10.1097/ gad.000000000001547
- 10. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

- enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-26. doi: 10.1016/s0140-6736(08)60423-7
- 11. Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malincarne L, et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thromb Haemost. 2013;110(2):349-57. doi: 10.1160/th12-07-0504
- 12. De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. Aids. 2010;24(9):1259-66. doi: 10.1097/ QAD.0b013e32833a2b02
- 13. Gagliardini R, Fabbiani M, Colafigli M, D'Avino A, Mondi A, Borghetti A, et al. Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIVinfected patients. J Chemother. 2017;29(5):299-307. doi: 10.1080/1120009x.2016.1269040